Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
| Market Cap | 3.02B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -517.18M |
| Shares Out | 88.29M |
| EPS (ttm) | -6.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,116,034 |
| Open | 35.04 |
| Previous Close | 35.31 |
| Day's Range | 33.94 - 35.16 |
| 52-Week Range | 16.45 - 62.21 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 54.71 (+60.11%) |
| Earnings Date | Jul 29, 2024 |
About BHVN
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $54.71, which is an increase of 60.11% from the latest price.
News
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 demon...
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the pote...
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven'...
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn. , April 22, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism...
How Biohaven's experimental obesity drug could prevent muscle loss
Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, ep...
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology
Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzh...
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous sy...
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242 million from completed public offering on O...
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including obesity. - Taldefgrobep monotherapy significant...
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd.
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
- Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass and adipose tissue - RESILIENT, the p...
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
Examination of EEG in healthy subjects administered single doses of BHV-7000 confirmed central nervous system (CNS) activity consistent with effects observed with other antiseizure medications. EEG re...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and Orphan Drug Designation in ...
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023 Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous...
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
NEW HAVEN, Conn. , July 27, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team's fourth NDA in approximately 3 years Released additional data fr...
Biohaven to Present R&D Day at Yale School of Management
NEW HAVEN, Conn. , May 25, 2023 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China) Appointed Nick Kozauer, M.D. a...